Genetic delivery of enzymes for cancer therapy.
Genetic delivery of enzymes for cancer therapy.
复制标题
用于癌症治疗的酶的基因传递。
作者：
Mahendra Deonarain;Robert A. Spooner;A. Epenetos
多年来，抗体一直被用作递送细胞毒性蛋白以杀死靶细胞（免疫毒素）的手段。最近，已经对将前药转化为活性药物以杀死靶细胞的酶进行了研究。基因治疗策略的进步现在允许人们将蛋白质或酶的基因作为替代。这种技术，虽然在它的婴儿期，承诺克服一些与抗体介导的传递相关的问题。胸苷激酶和胞嘧啶脱氨酶是目前正在以这种方式开发的一些酶，但更多的酶即将出现。然而，仍然需要更多的研究来充分利用肿瘤和正常细胞之间的转录差异，以便以这种方式治疗更多现有的癌症。
For many years, antibodies have been examined as means to deliver cytotoxic proteins to kill target cells (immunotoxins). More recently, there have been studies on enzymes that convert prodrugs to active drugs to kill target cells. The advances in gene therapy strategies now allow one to deliver the gene for the protein or enzyme as an alternative. This technique, although in its infancy, promises to overcome some of the problems associated with antibody-mediated delivery. Thymidine kinase and cytosine deaminase are some of the enzymes currently being exploited in this way, but more are on the horizon. However, more research is still needed to enable full exploitation of the transcriptional differences between tumour and normal cells so that more existing cancers can be treated in this way.